Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NexLife vs Teleios Health

NexLife
Graded #139

Higher grade

vs+8.5
Teleios Health
Graded #327

Lower grade

The verdict

NexLife takes it — 68.7/100 to 60.2/100.

NexLife grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NexLife is a LegitScript-certified telehealth platform offering compounded semaglutide (from $145/mo) and compounded tirzepatide (from $186/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTeleios Health +13
71
84
Dose & formulationEven
64
64
Clinical oversightNexLife +40
89
49
Labs & monitoringNexLife +5
53
48
FulfillmentNexLife +25
67
42
Contract termsEven
55
55
NexLife · left barTeleios Health · right bar

The numbers

MetricNexLifeTeleios Health
WeighScore68.7/10060.2/100
GradeCC
Scorecard rank#139#327
Semaglutide$165/mo (compounded)$99/mo (starting dose, compounded)
Tirzepatide$215/mo (compounded)$139/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
NexLife

Graded #139 · C

Strengths

  • LegitScript certified platform
  • Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
  • Both semaglutide and tirzepatide at competitive pricing
  • Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset

Where it loses points

  • State availability not publicly disclosed
  • Compounded only — no brand-name options
  • Also covers hormone optimization and longevity
  • Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment
Teleios Health

Graded #327 · C

Strengths

  • Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
  • Compounded tirzepatide from a competitive $139/mo floor
  • Markets physician (MD/DO) prescribing rather than an NP-only model
  • Clean meta-tag and SEO implementation

Where it loses points

  • Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
  • No named medical director, physician, or corporate entity disclosed
  • Year founded unknown — a newer floor-price entrant warranting extra scrutiny
  • No LegitScript, NABP, or SOC 2 trust signal found
  • Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard